AML Hub | Quarter Three 2020 Update

The AML Hub is a platform brought to you by Scientific Education Support (SES), who strive to bring increased knowledge and awareness to healthcare professionals via collaborative networks across the globe. The AML Hub strives to inform real-world clinical practice by providing the latest trial and drug updates, key literature, and congress coverage.

Guided by an Executive Steering Committee and Scientific Advisory Board of world-leading experts in acute myeloid leukemia (AML), the AML Hub, in association with the European LeukemiaNet (ELN), acts to disseminate the latest clinical updates in AML, ensuring healthcare teams are informed and patients with AML have access to the latest drugs and clinical trials.

In the third quarter of 2020, the AML Hub virtually attended the 46th European Society of Blood and Marrow Transplantation (EBMT) meeting and reported live updates via the social media channels, as well as providing summaries of key sessions and expert interviews. During this congress, the AML Hub hosted its first Satellite Symposium, where five international experts—Gert Ossenkoppele, Jacqueline Cloos, Christian Thiede, Adriano Venditti, and Charles Craddock—discussed how measurable residual disease impacts outcome of stem cell transplantation in AML, now and in the future. This symposium was one of the top 10 attended sessions at the EBMT meeting, with over 800 attendees spanning over 70 countries. The talks were also made available as summary articles on the AML Hub, with interactive polls to gauge user understanding on the topic.

Following this, in September, the AML Hub was in virtual attendance at the Annual Meeting of the Society of Hematologic Oncology (SOHO) and provided social media coverage of key sessions, summary articles, and expert interviews.

The AML Hub would like to welcome Gamida Cell as a contributor, and thank our gold supporters Genentech and Roche, silver supporters AbbVie, Amgen, Daiichi Sankyo, and Novartis, bronze supporters Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals, and Janssen Pharmaceuticals, and our contributors Agios and Helsinn for their continued support of the initiative.

For more information on the AML Hub, please visit https://aml-hub.com/.

For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com.